Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by A Ribed
DI-053 Adherence, quality of life and patient satisfaction with dalfampridine in clinical practice
Background Mobility impairment is a major concern for patients with multiple sclerosis (MS). Dalfampridine improves walking speed. Nevertheless, it entails self-administration and there are few data on adherence rate, patient satisfaction and quality of life (QOL) in clinical practice. Purpose To assess adherence, QOL and degree of patient satisfaction with dalfampridine in patients treated in our hospital.
DI-054 Safety results of direct acting antivirals for the treatment of hepatitis C virus infection
Background The recent development of new drugs has changed radically the treatment of chronic hepatitis C virus (HCV) infection, from interferon (IFN) based treatments to treatments based on direct acting antivirals (DAA). These drugs are thought to be better tolerated but data are still preliminary. Purpose The aim of this study was to evaluate the safety of DAA based treatment of HCV in clinical practice.
CP-219 Effectiveness and safety of switching to dual antiretroviral therapy in a treatment experienced HIV cohort
Background Long term adverse effects, expense and difficulty of adherence to antiretroviral therapy (ART) have led to the study of simpler maintenance therapies. Switching from triple therapy to dual therapy seems to be effective and safe, but few data exist in clinical practice. Purpose To assess the effectiveness and safety of simplification to a dual therapy in experienced HIV patients.
CP-102 Pharmaceutical care monitoring of hepatitis C outpatients: Guaranteeing safety and efficiency
Background The recent development of highly effective interferon free drug regimens has dramatically changed the therapeutic landscape of hepatitis C virus (HCV). An intensive pharmaceutical care programme is necessary, due to their recent commercialisation, the limited available data on their effectiveness and safety in clinical practice and their high cost. Inclusion criteria: patients who began treatment with NAD between April and September 2015.
CP-006 Ketoconazole and performance status as predictive factors of response to abiraterone in metastasic prostate cancer in real life conditions
Background Abiraterone is an oral antiandrogen therapy approved in September 2011 by the European Medicines Agency (EMA) for metastatic castration resistant prostate cancer (mCRPC) in men whose disease had progressed on a docetaxel based chemotherapy, and was included in our hospital´s formulary in 2012.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with A
Contact A, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack